Selectivity of Cholinesterase Inhibition

Alzheimer's Disease and Senile Dementia: Loss of Neurons in the Basal Forebrain

1982 • 3,563 citations

Atomic Structure of Acetylcholinesterase from Torpedo californica : A Prototypic Acetylcholine-Binding Protein

1991 • 2,613 citations

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

1998 • 1,575 citations

Molecular and cellular biology of cholinesterases

1993 • 1,192 citations

Oral Tetrahydroaminoacridine in Long-Term Treatment of Senile Dementia, Alzheimer Type

1986 • 1,148 citations

Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the Enzyme

1996 • 1,058 citations

The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial<sup>1</sup>

1999 • 581 citations

Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction

1996 • 503 citations

A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease

1998 • 473 citations

Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease

1994 • 448 citations

Responses of acetylcholinesterase from Torpedo marmorata to salts and curarizing drugs.

1966 • 308 citations

Chapter 53: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease

1993 • 302 citations

Butyrylcholinesterase in the life cycle of amyloid plaques

1997 • 294 citations

Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease

1998 • 290 citations

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

1998 • 289 citations

Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis.

1992 • 286 citations

Oral physostigmine and lecithin improve memory in Alzheimer disease

1983 • 282 citations

In vivo neurotoxicity of beta-amyloid [β(1–40)] and the β(25–35) fragment

1992 • 225 citations

Selective induction of Kunitz-type protease inhibitor domain-containing amyloid precursor protein mRNA after persistent focal ischemia in rat cerebral cortex

1991 • 206 citations

Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo

1990 • 205 citations

Molecular Forms of Acetylcholinesterase and Butyrylcholinesterase in the Aged Human Central Nervous System

1986 • 184 citations

Rivastigmine

1998 • 179 citations

Donepezil

2000 • 175 citations

Anatomy of cholinesterase inhibition in Alzheimer's disease: Effect of physostigmine and tetrahydroaminoacridine on plaques and tangles

1987 • 171 citations

Metrifonate treatment of the cognitive deficits of Alzheimer's disease

1998 • 170 citations

Regulation of regional cerebral blood flow by cholinergic fibers originating in the basal forebrain

1992 • 159 citations

Oxidative energy metabolism in Alzheimer brain

1992 • 156 citations

Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats

1994 • 151 citations

Multidisciplinary Approaches to Cholinesterase Functions

1992 • 128 citations

Donepezil Use in Alzheimer Disease

1998 • 126 citations

Neuropsychiatric Symptoms and Cholinergic Therapy for Alzheimer’s Disease

1999 • 120 citations

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

2009 • 120 citations

Donepezil

1997 • 120 citations

Comparative Studies of Huperzine A, E2020, and Tacrine on Behavior and Cholinesterase Activities

1998 • 117 citations

Dementia with Lewy bodies

1998 • 116 citations

Donepezil mediated memory improvement in traumatic brain injury during post acute rehabilitation

1998 • 114 citations

Impaired brain microcirculation may trigger Alzheimer's disease

1994 • 112 citations

Memory retention: potentiation of cholinergic drug combinations in mice

1983 • 107 citations

Secreted acetylcholinesterase: non-classical aspects of a classical enzyme

1992 • 105 citations

An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors

1996 • 103 citations

Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica

1998 • 103 citations

Physostigmine, tacrine and metrifonate: The effect of multiple doses on acetylcholine metabolism in rat brain

1989 • 103 citations

From Molecular Structure to Alzheimer Therapy.

1997 • 96 citations

Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and Tacrine

1991 • 96 citations

Tacrine and donepezil attenuate the neurotoxic effect of Aβ(25-35) in rat PC12 cells

1998 • 89 citations

Chapter 16 Molecular pathology of head trauma: altered βAPP metabolism and the aetiology of Alzheimer's disease

1993 • 89 citations

Effects of oral physostigmine in Alzheimer's disease

1987 • 87 citations

Immunolabelling of hippocampal microvessel glucose transporter protein is reduced in Alzheimer's disease

1994 • 87 citations

A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066

1999 • 86 citations

Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain

1990 • 85 citations

Progress in Alzheimer’s and Parkinson’s Diseases

1998 • 82 citations

The Role of Excitatory Amino Acids in Severe Brain Trauma: Opportunities for Therapy: A Review

1995 • 81 citations

Non-cholinergic actions of acetylcholinesterases: proteases regulating cell growth and development?

1990 • 78 citations

Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia

1986 • 78 citations

Oral physostigmine and lecithin improve memory in Alzheimer's disease.

1983 • 76 citations

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease

1999 • 73 citations

Influence of the cholinesterase inhibitor galanthamine hydrobromide on normal sleep

1994 • 73 citations

Rivastigmine, a Brain-Selective Acetylcholinesterase Inhibitor, Ameliorates Cognitive and Motor Deficits Induced by Closed-Head Injury in the Mouse

1998 • 70 citations

Clinical Profile of Donepezil in the Treatment of Alzheimer’s Disease

1999 • 69 citations

TIME COURSE OF EFFECTS OF UNILATERAL LESIONS OF THE NUCLEUS BASALIS OF MEYNERT ON GLUCOSE UTILIZATION BY THE CEREBRAL CORTEX

1989 • 69 citations

Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors.

1994 • 65 citations

Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK-247 in rats

1993 • 62 citations

Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patients with Alzheimer's disease*

1996 • 59 citations

Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease

1992 • 59 citations

Oral Tetrahydroaminoacridine Treatment of Alzheimer's Disease Evaluated Clinically and by Regional Cerebral Blood Flow and EEG

1993 • 59 citations

Galanthamine

1996 • 56 citations

Mapping the human acetylcholinesterase gene to chromosome 7q22 by fluorescent in situ hybridization coupled with selective PCR amplification from a somatic hybrid cell panel and chromosome-sorted DNA libraries

1992 • 54 citations

Effectiveness and Safety of Velnacrine for the Treatment of Alzheimer's Disease

1995 • 53 citations

Efficacy and safety of eptastigmine for the treatment of patients with Alzheimer’s disease

1999 • 53 citations

Brain Glucose Metabolism in Alzheimer’s Disease

1994 • 51 citations

Metrifonate improves spatial navigation and avoidance behavior in scopolamine-treated, medial septum-lesioned and aged rats

1996 • 50 citations

Tetrahydroaminoacridine alleviates medial septal lesion-induced and age-related spatial reference but not working memory deficits

1991 • 48 citations

Safety and Efficacy of Oral Physostigmine in the Treatment of Alzheimer Disease

1993 • 47 citations

Cholinesterase Inhibitors Do More than Inhibit Cholinesterase

1997 • 46 citations

Control of Platelet Production

1983 • 44 citations

Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in vivo pharmacological studies

1994 • 40 citations

Functional activation of cerebral blood flow abolished by scopolamine is reversed by cognitive enhancers associated with cholinesterase inhibition: a positron emission tomography study in unanesthetized monkeys.

1997 • 40 citations

Preferential inhibition of acetylcholinesterase molecular forms in rat brain

1992 • 40 citations

Combined Study of Cerebral Glucose Metabolism and [¹¹C]Methionine Accumulation in Probable Alzheimer's Disease Using Positron Emission Tomography

1996 • 39 citations

Inhibition of Acetylcholinesterase Modulates the Autoregulation of Cerebral Blood Flow and Attenuates Ischemic Brain Metabolism in Hypertensive Rats

1995 • 38 citations

Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat

1998 • 37 citations

Acetylcholinesterase inhibitor ENA-713 protects against ischemia-induced decrease in pre- and postsynaptic cholinergic indices in the gerbil brain following transient ischemia

1994 • 35 citations

Post-ischemic administration of the acetylcholinesterase inhibitor ENA-713 prevents delayed neuronal death in the gerbil hippocampus

1995 • 34 citations

Possible role of the cholinergic system and disease models

1997 • 34 citations

A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase

1994 • 34 citations

Physostigmine enhances blood flow-metabolism ratio in neocortex.

1988 • 34 citations

Molecular Forms of Butyrylcholinesterase in the Human Neocortex During Development and Degeneration of the Cortical Cholinergic System

1987 • 31 citations

Amyloidogenic processing of Alzheimer's amyloid precursor protein in vitro and its modulation by metal ions and tacrine

1996 • 31 citations

Abnormalities of the glucose transporter at the blood-brain barrier and in brain in Alzheimer's disease.

1989 • 31 citations

Safety and tolerability of metrifonate in patients with alzheimer's disease: Results of a maximum tolerated dose study

1998 • 28 citations

Prolonged Effects of Cholinesterase Inhibition with Eptastigmine on the Cerebral Blood Flow-Metabolism Ratio of Normal Rats

1993 • 26 citations

Biphasic effect of tacrine on acetylcholine release in rat brain via M1 and M2 receptors

1996 • 25 citations

Distribution of tacrine and metabolites in rat brain and plasma after single- and multiple-dose regimens. Evidence for accumulation of tacrine in brain tissue.

1996 • 24 citations

Effects of Metrifonate, a Cholinesterase Inhibitor, on Local Cerebral Glucose Utilization in Young and Aged Rats

1996 • 22 citations

Tacrine Development Experience

1994 • 19 citations

From Molecular Biology to Therapy

1988 • 18 citations

Double-blind placebo-controlled study of velnacrine in Alzheimer's disease

1996 • 16 citations

Metrifonate

1997 • 15 citations

Occurrence of acetylcholinesterase activity closely associated with amyloid ?/A4 protein is not correlated with acetylcholinesterase-positive fiber density in amygdala of Alzheimer's disease

1992 • 15 citations

Tacrine Treatment in Alzheimer's Disease Enhances Cerebral Blood Flow and Mental Status and Decreases Caregiver Suffering

1997 • 14 citations

Metabolic Response to Tacrine (THA) and Physostigmine in the Aged Rat Brain

1995 • 11 citations

Actions at Autonomic Effector Sites

1963 • 10 citations

Tacrine overcompensates for the decreased blood flow induced by basal forebrain lesion in the rat

1996 • 8 citations

Alzheimer's Patients Should Be Included in Phase I Clinical Trials To Evaluate Compounds for Alzheimer's Disease

1992 • 7 citations

Cryptic Catalysis and Cholinesterase Function

1992 • 6 citations

Increase in Cerebral Blood Flow and Glucose Utilization in Beneficial Effect of a Cholinesterase Inhibitor, Ena713 in Alzheimer’s Disease

1998 • 1 citations

Deleted Work

1955 • 0 citations